Intervacc (IVACC.ST) Stock Analysis & AI Equity Report

Biotechnology SEK Explore free reports

Intervacc (IVACC.ST) overview

Intervacc (IVACC.ST) stock analysis and AI equity research. For the latest completed financial year, 2025, Intervacc reported revenue of SEK 20.1m and operating profit of SEK -84.9m; the year-end share price was 0.92 SEK and market capitalisation was SEK 275m. Intervacc is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Intervacc's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.

Key metrics & valuation multiples

Book valueSEK 275mFY 2025
Share price0.92 SEKFY 2025 year end
RevenueSEK 20.1mFY 2025
Operating profitSEK -84.9mFY 2025
Net earningsSEK -80.8mFY 2025
Market capitalisationSEK 275mFY 2025 year end

Figures updated on 2026-07-27. Data will be refreshed during report generation.

About Intervacc

Intervacc AB is a Swedish biotechnology company focused on animal health. It develops veterinary vaccines based on recombinant proteins, with Strangvac as its main product against equine strangles. Through its subsidiary Nordvacc, the group markets veterinary vaccines and animal health products, while Mybac-Vettech provides accredited bacteriological and mycological diagnostic services in Sweden.

Generate the Intervacc report

Intervacc is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.

Generate fresh report — €50.00 Delivered by email, typically within about 30 minutes

Sources & methodology

Financial figures are sourced from Valuatum's financial model for Intervacc and represent the latest completed financial year (2025). See the methodology for the full Valuatum AI equity research framework.

Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.

Analyst reports on Intervacc

Each is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by what other analysts said the work added over the engine's report — a score out of five from people who had to read it to give it.